Sanofi

SNYNF

Held by 2 specialist biotech funds

2 funds opened new positions. Next phase2 readout (Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV): May 2000.

Drug Manufacturers - GeneralCEO: Olivier CharmeilIPO: 2008Website ↗

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Catalysts

Phase 2Q2 2000Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPVPertussis, Tetanus, DiphtheriaNCT02040636

Primary: Seroprotection against diphtheria and tetanus antigens after vaccination with either Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis (Tdcp-IPV) or concurrent Tdcp-IPV and Hepatitis B vaccine (Day 0 (pre-vaccination) and 1 month, 3, 5 and 10 years post-vaccination)Enrollment:277/277Sites: 1RANDOMIZED, PREVENTION

Phase 3Q3 2002GlimepirideDiabetes Mellitus, Non-Insulin-DependentNCT00044447

Primary: Change in HbA1C from baseline to Week 26.Enrollment:170/170Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2002Insulin glargineDiabetes Mellitus, Type 2NCT01336751

Primary: Change from baseline in hemoglobin A1c (HbA1c) levels at week 24 (24 weeks)Enrollment:212/212Sites: 1RANDOMIZED, TREATMENT

Phase 2Q1 2003DocetaxelCarcinoma, Non-Small-Cell LungNCT00819728

Enrollment:35/35Sites: 1NA, TREATMENT

Phase 2Q1 2003Vasopressin V2 Receptor AntagonistChronic Heart FailureNCT00032747

Primary: Clinical status at day 120.Enrollment:338/338Sites: 9RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2003Oxaliplatin, 5-FUHead and Neck CancerNCT00611754

Primary: To evaluate the efficacy of first line oxaliplatin in combination with 5-fluorouracil (5-FU) in patients with advanced inoperable or metastatic head and neck cancer.Enrollment:15/15Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ1 2003ACAM1000SmallpoxNCT00053508

Primary: The proportion of subjects in each treatment group who develop a major cutaneous reaction on Day 7, Day 10, and/or Day 15. (Day 7, Day 10, and/or Day 15)Enrollment:274/274Sites: 3RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q2 2003Thymoglobulin [Anti-thymocyte Globulin (rabbit)]Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction TherapyNCT00235300

Primary: Freedom from acute rejection, kidney transplant loss, delayed kidney transplant function and death at 6 months after transplant. (6 months)Enrollment:240/240Sites: 28RANDOMIZED, PREVENTION

Phase 3Q2 2003XRP6976Stomach NeoplasmNCT00290966

Primary: to detect a significant increase in time to progression in favor of docetaxel plus cisplatin and 5-FU compared to cisplatin plus 5-FU. Tumor assessments (assessed with WHO criteria) had to be performed every 8 weeks until progressionEnrollment:Target 610RANDOMIZED, TREATMENT

Phase 2Q3 2003GT160-246Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis, Clostridium Difficile DiarrheaNCT00034294

Enrollment:Target 300Sites: 99RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2003OxaliplatinUterine NeoplasmsNCT00782041

Primary: Response rate (Throughout the study period)Enrollment:11/11Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q3 2003Insulin GlargineDiabetes Mellitus, Type 2NCT00783744

Primary: Frequency of subjects with HbA1c ≤ 7.0 % and > 7.0 % (At endpoint)Enrollment:375/375Sites: 10RANDOMIZED, TREATMENT

Phase 3Q3 2003RimonabantSmoking CessationNCT00358228

Primary: Prolonged abstinence from tobacco smoking during the last 4 weeks of treatment (Day 43 to Day 70) as reported by direct inquiry of the patient by the Investigator, and confirmed by exhaled carbon monoxide (CO) levels, and plasma cotinine measurements.Enrollment:787/787Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2003Dronedarone (SR33589)Atrial Fibrillation, Atrial FlutterNCT00259428

Primary: The primary endpoint of the study is the time from randomisation to first documented AF/AFL recurrenceEnrollment:615/615Sites: 12RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2003Thyrogen + Radioiodine (131I)Thyroid NeoplasmsNCT00196729

Primary: Use of Thyrogen in euthyroid patients undergoing radioiodine remnant ablation with 100 mCi (3.7 GBq) 131I results in a comparable ablation rate to patients undergoing radioiodine remnant ablation in the hypothyroid state with 100 mCi (3.7 GBq) 131IEnrollment:Target 63RANDOMIZED

Phase 2Q3 2003Human Anti-Transforming Growth Factor Beta-1 Monoclonal AntibodySystemic Sclerosis, SclerodermaNCT00043706

Sites: 4TREATMENT

Phase 3Q3 2003TelithromycinMaxillary SinusitisNCT00537563

Primary: To demonstrate equivalence in clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure (TOC) visit. (Days 17 to 24)Enrollment:351/351Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2003FexofenadineAsthmaNCT00044824

Primary: Change from baseline in Forced Expiratory Volume FEV1Enrollment:Target 1,000Sites: 7RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2004zolpidem-MR (modified release)Sleep Initiation and Maintenance DisordersNCT00630175

Primary: Polysommography (PSG) wake time after sleep onset (WASO)Enrollment:113/113Sites: 3RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2004cisplatinLung CancerNCT00017459

Sites: 42TREATMENT

Phase 3Q2 2004Rimonabant (SR141716)Obesity, Weight LossNCT00029861

Primary: Change in body weightEnrollment:3,045/3,045Sites: 51RANDOMIZED, DOUBLE, PREVENTION

Phase 2Q2 2004ZD6474Multiple MyelomaNCT00047788

Enrollment:Target 30Sites: 7NON_RANDOMIZED, TREATMENT

Phase 2Q2 2004Live attenuated Japanese encephalitis virus, then ChimeriVax diluentEncephalitis, Japanese EncephalitisNCT00981175

Primary: Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Dose (Day 28 post-vaccination)Enrollment:202/202Sites: 1RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q3 2004sodium hyaluronateOsteoarthritis of ShoulderNCT00377624

Primary: Improvement in shoulder pain on movement in previous 24 hours, based upon 100 mm VAS score up to 3 months after baseline for the 3 i.a. and 5 i.a. sodium hyaluronate injections compared to PB-Saline controlEnrollment:Target 602Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2004Telithromycin (HMR3647)Otitis MediaNCT00638534

Primary: Safety evaluation: presence/absence of subjective/objective symptoms and abnormal laboratory findingsEnrollment:56/56Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q4 2004AlfuzosinProstatic Hyperplasia, Acute Urinary RetentionNCT00290030

Primary: Successful voiding in initial period (using an active voiding trial)Enrollment:800/800RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2005Rasburicase (SR29142)HyperuricemiaNCT00664144

Primary: responder rate (based on normalization of uric acid levels)Enrollment:33/33Sites: 4NON_RANDOMIZED, TREATMENT

Phase 2Q1 2005oxaliplatin, 5 FUEndometrial CancerNCT00612495

Primary: Overall RR (World Health Organization [WHO]/Union Internationale Contre le Cancer [International Union Against Cancer] [UICC] criteria (during the study conduct)Enrollment:31/31Sites: 1RANDOMIZED, TREATMENT

Phase 2Q2 2005XRP0038 (NV1FGF)Peripheral Arterial DiseaseNCT00368797

Primary: Primary efficacy parameter: ulcer healing.Enrollment:125/125Sites: 6RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2005Live attenuated Japanese encephalitis virus; Yellow fever virusJapanese Encephalitis, Yellow FeverNCT00982137

Primary: Number of Participants With Japanese Encephalitis Seroconversion Following ChimeriVax™-JE or STAMARIL® Alone or the Co-administration of ChimeriVax™-JE and STAMARIL®, or Placebo Vaccination. (Pre-vaccination (Day 0 or 30) and post-vaccination (Day 30 or 60))Enrollment:108/108Sites: 1RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q2 2005Docetaxel and GemcitabineNon-small Cell Lung CancerNCT00425191

Primary: Response Rate (Performed after 3 cycles and at the end of treatment (6 cycles).)Enrollment:165/165Sites: 1RANDOMIZED, TREATMENT

Phase 2Q2 2005DOCETAXELBreast NeoplasmsNCT00617968

Primary: Rate of clinical and radiological response evaluated according to RECIST criteria (During the study conduct)Enrollment:5/5Sites: 1RANDOMIZED, TREATMENT

Phase 2Q2 2005oxaliplatinColorectal CancerNCT00399750

Primary: To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2)Enrollment:Target 373Sites: 1RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2005G-CSF plus plerixaforMultiple Myeloma, Lymphoma, Non-Hodgkin'sNCT00395967

Primary: Number of Patients Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor 240 µg/kg and G-CSF for up to 3 Consecutive Days (approximately days 6-9)Enrollment:5/5Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q3 2005SL77.0499-10 (alfuzosin hydrochloride)Benign Prostatic HyperplasiaNCT00409357

Primary: The primary efficacy assessment is the change from baseline in International Prostate Symptom Score (IPSS) total score at the end-of-study (EOS) visit.Enrollment:473/473Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2005XRP0038 (NV1FGF)Peripheral Arterial Occlusive DiseaseNCT01157871

Primary: Change from baseline in Absolute Claudication Distance (ACD) evaluated by treadmill test at week 13 (13 weeks)Enrollment:36/36Sites: 4RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2005Enoxaparin sodiumPercutaneous Coronary InterventionNCT00077844

Primary: the composite of non-CABG major and minor bleeding (up to H48 after index PCI)Enrollment:Target 3,532RANDOMIZED, PREVENTION

Phase 3NegativeQ3 2005clopidogrel (SR25990C)Atrial Fibrillation, Vascular RiskNCT00243178

Primary: Primary outcome:time to the first occurrence of stroke, non-CNS systemic embolism, myocardial infarction or vascular death (during approximately three years of follow-up)Enrollment:6,706/6,706Sites: 32RANDOMIZED, PREVENTION

Phase 2Q4 2005Sargramostim (Leukine)Crohn DiseaseNCT00206596

Primary: Corticosteroid-free remission (At the end of the study treatment)Enrollment:127/127RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2005OXALIPLATINRectal NeoplasmsNCT00403624

Primary: Tumour responseEnrollment:Target 38NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2005SR147778ObesityNCT00239174

Primary: Weight loss at 6 months.Enrollment:394/394Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2005Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]Renal Transplantation, Graft RejectionNCT00089947

Primary: This study will evaluate the effect of Thymoglobulin and reduced doses of steroids to prevent renal transplant rejection, organ loss and death at 6 months.Enrollment:Target 150Sites: 19RANDOMIZED, TREATMENT

Phase 2Q4 2005ILX651Hormone-refractory Prostate CancerNCT00082134

Enrollment:Target 40Sites: 12NON_RANDOMIZED, TREATMENT

Phase 3Q4 2005SR34006 (idraparinux sodium) InjectionPulmonary Embolism, Deep Vein ThrombosisNCT00071279

Primary: Symptomatic recurrent PE/DVT during the 6-month study treatment period.Enrollment:1,215/1,215Sites: 65RANDOMIZED, DOUBLE

Phase 2NegativeQ1 2006ILX651MelanomaNCT00068211

Sites: 19NON_RANDOMIZED, TREATMENT

Phase 2PositiveQ1 2006clofarabine (IV formulation)Leukemia, Lymphoblastic, Acute, PediatricNCT00042341

Enrollment:Target 60Sites: 14NON_RANDOMIZED, TREATMENT

Phase 3Q1 2006OsteoarthritisNCT00131768

Primary: Pain reliefSites: 5NON_RANDOMIZED, TREATMENT

Phase 3Q1 2006ClopidogrelThrombosisNCT00716924

Primary: Incidence of post-percutaneous coronary intervention elevation of troponin T. (At 6 and 12 months post-PCI)Enrollment:155/155Sites: 1RANDOMIZED, TREATMENT

Phase 3Q1 2006Inactivated Poliomyelitis vaccinePoliomyelitisNCT00258843

Enrollment:40/40Sites: 1NON_RANDOMIZED, PREVENTION

Phase 2Q1 2006Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)Meningitis, Meningococcal InfectionNCT00643916

Primary: Percentage of Participants With a ≥8 Antibody Titers as Measured by Serum Bactericidal Assay Human Complement (SBA-HC) After Each Vaccination. (Day 0 (baseline) and Day 28 post-Vaccinations 1 and 2)Enrollment:378/378Sites: 14NON_RANDOMIZED, PREVENTION

Phase 2Q2 2006MyozymePompe Disease Late-Onset, Glycogen Storage Disease Type II GSD IINCT00765414

Primary: The objective of this extension study was to monitor the long-term safety and efficacy of a single patient (3 years)Enrollment:1/1Sites: 1NA, TREATMENT

Phase 2Q2 2006rimonabant (SR141716)ObesityNCT00459004

Primary: absolute change in body weight from baseline to Week 24Enrollment:527/527Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2006CELIVARONE (SSR149744C)Atrial Fibrillation, Atrial FlutterNCT00232310

Primary: The primary efficacy endpoint is the rate of conversion to sinus rhythm documented by ECG just before the planned electrical cardioversion on D3 i.e. after 48 hours following the first study drug administration.Enrollment:150/150Sites: 9RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2006rasburicase (SR29142)Nutritional and Metabolic DiseasesNCT00290992

Primary: Patients with a plasma uric acid level decreased to the endpoint by 48 hr after the start of first drug infusion and lasting until 24 hr after the start of final (Day 5) drug infusion.Enrollment:30/30Sites: 1TREATMENT

Phase 2Q2 2006docetaxel and cisplatinHead and Neck NeoplasmsNCT00521521

Primary: Objective response rates (evaluated 8 weeks after the end of radiotherapy)Enrollment:86/86Sites: 1RANDOMIZED, TREATMENT

Phase 2Q2 2006SSR240600COveractive BladderNCT00174798

Primary: Change in bladder capacity as determined by cystometric parameters from baseline to end of treatment.Enrollment:118/118Sites: 22RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2006ChimeriVax™-JEJapanese EncephalitisNCT00314145

Primary: Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion Following Either ChimeriVax™-JE or JE-Vax® Vaccination (Up to Day 60 post-first vaccination)Enrollment:820/820Sites: 10RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3PositiveQ2 2006alemtuzumabB Cell Chronic Lymphocytic LeukemiaNCT00046683

Primary: Campath vs. chlorambucilEnrollment:Target 284Sites: 20RANDOMIZED, TREATMENT

Phase 2PositiveQ2 2006G-CSF Plus PlerixaforLymphoma, Non-Hodgkin, Multiple MyelomaNCT00322491

Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) (Day 1 to approximately Day 38 (before start of chemotherapy))Enrollment:49/49Sites: 8NON_RANDOMIZED, TREATMENT

Phase 2Q2 2006Influenza virus vaccine (2004-2005 Formulation)InfluenzaNCT00858468

Primary: Percentage of Participants With Solicited Local and Systemic Reactions After Vaccination With Fluzone® 2004-2005 Pediatric Formulation. (Day 0 to Day 7 post-vaccination)Enrollment:394/394Sites: 8RANDOMIZED, PREVENTION

Phase 2PositiveQ2 2006MVA Smallpox vaccineSmallpoxNCT00466245

Primary: Safety (Study Completion)Enrollment:590/590RANDOMIZED, TRIPLE, PREVENTION

Phase 2Q3 2006SR31747AProstatic NeoplasmNCT00174863

Primary: Time To Clinical Progression assessed by every 4 weeks clinical examination and every 12 weeks radiological examinations (Thoraco-abdominopelvic CT scan ; Bone scan ± centered Bone X-rays, MRI)Enrollment:232/232Sites: 13RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2006Nolpitantium besylateUlcerative Colitis, Inflammatory Bowel DiseaseNCT00232258

Primary: Clinical remission at 8 weeks defined as a clinical Mayo subscore </= 1Enrollment:307/307Sites: 14RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ3 2006TelithromycinTonsillitis, PharyngitisNCT00315549

Primary: To compare the bacteriologic efficacy of 5-days of telithromycin to 10-days of penicillin V insubjects at the posttherapy/test-of-cure (TOC) visit in the per protocol population.Enrollment:233/233Sites: 4RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2006Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Mucopolysaccharidosis I, Hurler Syndrome, Hurler-Scheie SyndromeNCT00258011

Primary: Safety Evaluation (Up to 73 Weeks)Enrollment:3/3Sites: 2NA, TREATMENT

Phase 3PositiveQ4 2006Granulocyte colony-stimulating factor plus plerixaforMultiple MyelomaNCT00103662

Primary: Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis. (up to Day 6)Enrollment:302/302Sites: 39RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2006OxaliplatinCarcinoma, HepatocellularNCT00280618

Primary: Time to Tumor Progression (TTP) and Response Rate: evaluated by RECIST (During the Study Conduct)RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2006Sargramostim (Leukine)Crohn DiseaseNCT00206661

Primary: Characterize the safety profile of sargramostim treatment with concomitant corticosteroid induction therapy (12 weeks)Enrollment:22/22Sites: 7NON_RANDOMIZED, TREATMENT

Phase 3Q4 2006Saredutant succinate (SR48968C)Depressive DisorderNCT00256113

Primary: The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.Enrollment:467/467Sites: 8RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2006Enoxaparin sodium (XRP4563)Myocardial Infarction, Acute ST-Segment ElevationNCT00077792

Primary: Composite of all-cause mortality and non-fatal myocardial re-infarctionEnrollment:20,506/20,506Sites: 48RANDOMIZED, DOUBLE, PREVENTION

Phase 3Q1 2007SODIUM DIVALPROATEBipolar DisorderNCT00271258

Primary: clinical examinationEnrollment:Target 200Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q1 2007SR58611AMajor Depressive DisorderNCT00252330

Primary: 17-item Hamilton Depression Rating Scale (HAM-D) total scoreEnrollment:476/476Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ1 2007tolevamer potassium-sodium (GT267-004)Clostridium Enterocolitis, Pseudomembranous ColitisNCT00106509

Primary: Resolution of diarrheaEnrollment:Target 520Sites: 140RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2007SSR149744CArrhythmia, Tachycardia, Ventricular, Ventricular FibrillationNCT00232297

Primary: Primary endpoint is time to all ventricular tachycardia or ventricular fibrillation arrhythmia leading to any ICD intervention (anti-tachycardia pacing or ICD shock).Enrollment:153/153Sites: 8RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2007REPEVAX® after REVAXIS®Healthy AdultNCT00400309

Primary: injection sites reactions and systemic events during the 7 day-safety period post-vaccination with TdaP-IPV vaccine. (7 days)Enrollment:500/500Sites: 4RANDOMIZED, DOUBLE, PREVENTION

Phase 2Q1 2007XRP9881Breast CancerNCT00087958

Primary: Objective response rate as assessed by Response Evaluation Criteria in Solid TumorsEnrollment:168/168Sites: 15NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2007Rimonabant (SR141716)Dyslipidemia, ObesityNCT00239967

Primary: HDL cholesterol and TG plasma levels over a period of one year.Enrollment:803/803Sites: 14RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2007Facial WrinklesNCT00417469

Primary: To evaluate the pain experienced during and after the injection procedure for NADGL as compared to Captique® Injectable Gel in subjects undergoing cutaneous correction of nasolabial folds (NLFs).Enrollment:Target 45Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 3NegativeQ2 2007triamcinolone acetonideRhinitisNCT00344942

Primary: Mean global score obtained on the basis of 5 evaluations : nasal obstruction, rhinorrhea, disturbed sense of smell, sneezing, facial heaviness. (7 days prior to each visit)Enrollment:77/77Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2007DTaP-IPV//PRP~T combined vaccineDiphtheria, Tetanus, PertussisNCT00303316

Primary: Summary of Antibody Persistence at 18 Months of Age in Participants That Received Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age. (Day 0 (Before booster vaccination))Enrollment:458/458Sites: 1NON_RANDOMIZED, PREVENTION

Phase 2NegativeQ2 2007Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)Ischemic Heart Failure, Ischemic Heart Disease, Ischemic CardiomyopathyNCT00102128

Primary: Recovery of contractility within previously akinetic areas of the heart (areas without motion/contraction) that have received treatment (cells from the patient's thigh muscle or placebo), and change in left ventricular EF as assessed by echocardiographySites: 28RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2007Saredutant succinate (SR48968C)Depressive DisorderNCT00250653

Primary: The primary outcome is the proportion of patients experiencing at least one treatment-emergent adverse event.Enrollment:365/365Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q2 2007SR58611ADepressive DisorderNCT00319709

Primary: The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.Enrollment:288/288Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2007gemcitabine/Eloxatin (GEMOX)Carcinoma, Non-Small-Cell LungNCT00087802

Primary: To determine the relative efficacy, safety and clinical benefit of the GEMOX regimen compared to the standard combination regimen of CP as first-line treatment of Stage IIIB and IV NSCLC (22 months)Enrollment:383/383Sites: 70RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2007SR123781AVenous ThromboembolismNCT00338897

Primary: The primary efficacy endpoint is a composite of total venous thromboembolic events (VTE) including VTE related deaths during the treatment period.Enrollment:1,090/1,090Sites: 14RANDOMIZED, DOUBLE, PREVENTION

Phase 3Q2 2007DT5aP-IPV-Hib 5-component Pertussis vaccinePertussis, Diphtheria, TetanusNCT00287092

Primary: To provide information concerning the immunogenicity of PEDIACEL® Vaccine. (1 Month post-dose 3)Enrollment:807/807Sites: 14RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q2 2007Hexadecasaccharide (SR123781A)Coronary AtherosclerosisNCT00123565

Primary: Efficacy: composite of all causes of death, new myocardial infarction, or severe myocardial ischemia requiring urgent repeat target vessel revascularization within 7 days following randomization.Enrollment:1,257/1,257Sites: 18RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2007Semuloparin sodiumVenous ThromboembolismNCT00331838

Primary: Number of Participants Who Experienced Venous Thromboembolism Event (VTE) or VTE-related Death (From surgery to Day 11 or the day of mandatory venography, whichever came first)Enrollment:705/705Sites: 19RANDOMIZED, TRIPLE, PREVENTION

Phase 2Q2 2007AVE1625 BObesity, DyslipidemiaNCT00345410

Primary: Absolute change from baseline in body weight at 24 weeksEnrollment:345/345Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2007insulin glulisineDiabetes Mellitus, Type 2NCT00135096

Primary: Compare change in weight from baseline to study week 52 in the per-protocol population of premeal Apidra vs postmeal Apidra, in patients receiving Lantus as basal insulin (52 weeks)Enrollment:345/345Sites: 1RANDOMIZED, TREATMENT

Phase 2Q3 2007Inactivated influenza vaccine (split virion) NH 2007-2008 formulationInfluenza, Orthomyxoviridae InfectionsNCT00491257

Primary: To provide information concerning the immunogenicity of 2007-2008 Influenza vaccine (split virion, inactivated). (21 Days post-vaccination)Enrollment:130/130Sites: 2NON_RANDOMIZED, PREVENTION

Phase 2NegativeQ3 2007DENSPM )Carcinoma, HepatocellularNCT00081900

Primary: To determine the overall safety profile of DENSPM intravenous infusion in patients with unresectable HCC. (8 months)Enrollment:38/38Sites: 8NON_RANDOMIZED, TREATMENT

Phase 3Q3 2007SR121463BCongestive Heart FailureNCT00274326

Primary: EFFICACY:Serum SodiumEnrollment:Target 150Sites: 15RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2007AVE1625Alzheimer DiseaseNCT00380302

Primary: Safety and tolerability throughout the study:adverse events collected by spontaneous reportEnrollment:162/162Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ3 2007GT267-004 (tolevamer potassium sodium)Enterocolitis, Pseudomembranous, Diarrhea, Clostridium DifficileNCT00466635

Primary: Clinical SuccessEnrollment:Target 65Sites: 13NON_RANDOMIZED, TREATMENT

Phase 2Q3 2007Oxaliplatin (SR96669)Gastrointestinal CancerNCT00094965

Primary: Adverse events. (12 Cycles)Enrollment:43/43Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q3 2007Inactivated influenza vaccine (split virion)Influenza, Orthomyxoviridae InfectionsNCT00343681

Primary: To provide information concerning the immunogenicity of inactivated influenza vaccine (split virion) (21 Days post-vaccination)Enrollment:120/120Sites: 2NA, PREVENTION

Phase 3Q3 2007DT5aP-IPV-Hib 5-component Pertussis vaccineInfant, HealthyNCT00355654

Primary: To provide information concerning the safety after administration of PEDIACEL® booster dose (0 to 3 Days post-vaccination)Enrollment:847/847Sites: 84RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q3 2007Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabineLung NeoplasmsNCT00258739

Primary: Response rate in each arm measured according to RECIST criteria (Throughout the whole study)Enrollment:140/140Sites: 1RANDOMIZED, TREATMENT

Phase 3NegativeQ4 2007xaliproden (SR57746A)Alzheimer DiseaseNCT00103649

Primary: Alzheimer's Disease assessment scale-cognitive, clinical dementia rating sum of boxes.Enrollment:1,306/1,306Sites: 121RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2007FOLFOX 4Esophageal NeoplasmsNCT00160030

Primary: Percentage of patients having completed the full treatment and Endoscopic complete response rate (at the end of the study)Enrollment:97/97Sites: 1RANDOMIZED, TREATMENT

Phase 2Q4 2007ZD6474Carcinoma, Non-Small-Cell LungNCT00071188

Sites: 34RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2007alfuzosinProstatic HyperplasiaNCT00399464

Primary: Change in I-PSS (International Prostate Symptom Score) total score from baseline to endpoint (Day 84 or last available post-baseline assessment)Enrollment:1,177/1,177Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2007eplivanserin (SR46349)Sleep Initiation and Maintenance Disorders, InsomniaNCT00253903

Primary: Change from baseline of the mean pr-WASO (wake time after sleep onset using patient's sleep questionnaire) (at week 12)Enrollment:1,155/1,155Sites: 14RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2007DTaP-HB-PRP~T vaccine + OPVDiphtheria, Tetanus, PertussisNCT00343889

Primary: Number of Participants With Seroprotection to Hepatitis H Antigen After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV (1 month post third vaccination)Enrollment:379/379Sites: 2RANDOMIZED, SINGLE, PREVENTION

Phase 3Q4 2007Bacillus ClausiiGastroenteritisNCT00457353

Primary: Reduction in duration of diarrhea (Throughout the treatment period)Enrollment:264/264Sites: 1RANDOMIZED, TREATMENT

Phase 2Q4 2007G-CSF Plus PlerixaforMultiple Myeloma, Lymphoma, Non-HodgkinNCT00396266

Phase 3NegativeQ1 2008TirapazamineHead and Neck Squamous Cell CarcinomaNCT00174837

Primary: Overall survival (Study period)Enrollment:317/317Sites: 17RANDOMIZED, TREATMENT

Phase 3Q1 2008saredutant (SR48968)Depressive DisorderNCT00415142

Primary: Change from baseline to Day 56 in the 17-item Hamilton Depression Rating Scale (HAM-D) total score. (Day 56)Enrollment:393/393Sites: 8RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2008SaredutantGeneralized AnxietyNCT00390533

Primary: Change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score. (56 days)Enrollment:428/428Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2008SR58611AMajor Depressive DisorderNCT00432614

Primary: Change from baseline in Hamilton Depression Rating scale (HAM-D) total score (8 weeks)Enrollment:510/510Sites: 13RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2008Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapyHead and Neck NeoplasmsNCT00357149

Primary: Rate of radiologic Complete Response (CR) evaluated 6-8 weeks after the completion of treatment (from end of treatment until 6-8 weeks)Enrollment:101/101Sites: 1RANDOMIZED, TREATMENT

Phase 3Q1 2008Lactic acid (Dermacid)HealthyNCT00668486

Primary: The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. The sensibility will be evaluated according to the skin type. (5 weeks)Enrollment:28/28Sites: 1NON_RANDOMIZED, SUPPORTIVE_CARE

Phase 2Q1 2008larotaxel (XRP9881)Advanced Breast Cancer, Breast Cancer, Metastatic Breast CancerNCT00387907

Primary: Tumor response measured (every 2 cycles during treatment phase)Enrollment:6/6Sites: 1NA, TREATMENT

Phase 3Q2 2008DTaP-IPV combined vaccinePertussis, Diphtheria, PoliomyelitisNCT00319852

Primary: To provide information concerning the immunogenicity of Sanofi Pasteur's DTaP-IPV combined vaccine versus commercially available Biken's DTaP and Aventis Pasteur's IPV (IMOVAX POLIO) monovalent vaccines. (1 month post-vaccination)Enrollment:442/442Sites: 1RANDOMIZED, PREVENTION

Phase 2NegativeQ2 2008surinabant (SR147778)Smoking CessationNCT00432575

Phase 3PositiveQ2 2008DTaP-IPV-HB-PRP~T vaccineDiphtheria, Tetanus, PertussisNCT00404651

Primary: Equivalence of Seroprotection Against Vaccine Antigens in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine (Day 150 (one month post-dose 3))Enrollment:1,189/1,189Sites: 6RANDOMIZED, SINGLE, PREVENTION

Phase 3Q2 2008Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccineDiphtheria, Tetanus, PolioNCT00259337

Primary: To provide information concerning the safety of DTacP-IPV//PRP~T combined vaccine (19 months)Enrollment:226/226Sites: 1NON_RANDOMIZED, PREVENTION

Phase 3NegativeQ2 2008SaredutantGeneralized AnxietyNCT00417118

Primary: Change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score. (Baseline, Day 56)Enrollment:365/365Sites: 7RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2008Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)Neoplasms, Cancer of the OvaryNCT00327171

Primary: Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon's Cohort (From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months))Enrollment:218/218Sites: 11RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2008FluBlok®InfluenzaNCT00539981

Primary: Number of Participants Reporting Solicited Injection Site (Local) Reactions (Within 7 days post vaccination)Enrollment:4,648/4,648Sites: 24RANDOMIZED, TRIPLE, PREVENTION

Phase 3Q2 2008Diphtheria, Tetanus, Polio, Acellular Pertussis and HibDiphtheria, Tetanus, Haemophilus InfectionsNCT00254969

Primary: To provide information concerning the immunogenicity of DTacP-IPV//PRP~T combined vaccine. (1 month post-vaccination)Enrollment:212/212Sites: 1NON_RANDOMIZED, PREVENTION

Phase 3Q2 2008Hepatitis A vaccine AVAXIM 80UHepatitis ANCT00483470

Primary: To provide information concerning the immunogenicity of AVAXIM 80U Pediatric vaccine (1 month post-vaccination)Enrollment:720/720Sites: 3RANDOMIZED, PREVENTION

Phase 2Q2 2008SSR150106Rheumatoid ArthritisNCT00545454

Primary: Change from baseline in mean C-Reactive Protein level (end of the 4-week double-blind treatment period)Enrollment:79/79Sites: 7RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2008Insulin GlulisineDiabetes MellitusNCT00467376

Primary: Hypoglycemic episodes (From the beginning to end of the study)Enrollment:485/485Sites: 1RANDOMIZED, TREATMENT

Phase 3Q2 2008PEDIACEL® and Prevenar®Diphtheria, Tetanus, PertussisNCT00343421

Primary: To provide information concerning the immunogenicity of PEDIACEL® and Infanrix®-IPV+Hib (1 month post-vaccination)Enrollment:588/588Sites: 2RANDOMIZED, SINGLE, PREVENTION

Phase 2NegativeQ3 2008SSR180711CAlzheimer's DiseaseNCT00602680

Primary: Change in cognitive performance (4 weeks)Enrollment:1/1Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2008Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)Pulmonary Diseases, Neoplasms, LungNCT00284141

Primary: Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC). (up to 2.5 years from initial treatment)Enrollment:98/98Sites: 3NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2008docetaxelNon-small Cell Lung CancerNCT00378573

Primary: Progression Free Survival for Subjects With Locally Advanced or Metastatic (Stage IIIB or Stage IV) Non-Small Cell Lung Cancer (NSCLC) After Systemic Treatment With Gemcitabine, Docetaxel, and Bevacizumab as First Line Therapy (1 year post-registration)Enrollment:17/17Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q3 2008insulin glulisine / insulin glargineDiabetes Mellitus, Type 1NCT00271284

Primary: Efficacy data : fasting blood glucose concentration (read daily during the last 2 months of each period)Enrollment:88/88Sites: 1RANDOMIZED, TREATMENT

Phase 3Q3 2008DTaP-HB-PRP~T vaccineDiphtheria, Tetanus, PertussisNCT00534833

Primary: Summary of Antibody Persistence and Immunogenicity Booster Response in Participants Who Were Vaccinated With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV (28 Days post-vaccination)Enrollment:362/362Sites: 2NON_RANDOMIZED, PREVENTION

Phase 3Q3 2008Poliomyelitis Vaccine inactivatedPoliomyelitis, PolioNCT00348387

Primary: To provide information concerning the immunogenicity of IMOVAX Polio™ vaccine (1 month post-vaccination 3)Enrollment:600/600Sites: 2RANDOMIZED, PREVENTION

Phase 3Q4 2008volinanserin (M100907)Sleep Initiation and Maintenance DisordersNCT00495885

Primary: change from baseline to 12 weeks for Sleep Maintenance Insomnia using patient reported Wake After Sleep Onset (pr-WASO) (12 weeks)Enrollment:848/848Sites: 16RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2008docetaxel, doxorubicin, cyclophosphamideBreast CancerNCT00312208

Primary: Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival) (Median follow-up 65 months)Enrollment:3,299/3,299Sites: 37RANDOMIZED, TREATMENT

Phase 2Q4 2008ataciguat (HMR1766)Intermittent ClaudicationNCT00443287

Primary: Primary efficacy endpoint: percent change in initial claudication distance (ICD) measured at the 26-week treadmill test, compared with ICD measured at baseline (26 weeks)Enrollment:553/553Sites: 7RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ4 2008SatavaptanAscites, Liver CirrhosisNCT00359437

Primary: Number and time of recurrences of therapeutic paracenteses (up to 12 weeks)Enrollment:501/501Sites: 24RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2008Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)Esophageal NeoplasmsNCT00259402

Primary: Efficacy endpoints include tumor response, progression free and overall survival. (Throughout the whole study)Enrollment:41/41Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ4 2008AVE5530HypercholesterolemiaNCT00718965

Primary: percent change from baseline in calculated LDL-C (at week 12)Enrollment:826/826Sites: 2RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ4 2008rimonabant (SR141716)ObesityNCT00434096

Primary: body weight: relative change from baseline (Week 52)Enrollment:915/915Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2008Lactic AcidHygieneNCT00783640

Primary: The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. (Throughout the study)Enrollment:27/27Sites: 1NON_RANDOMIZED, SUPPORTIVE_CARE

Phase 3Q4 2008Lactic AcidHygieneNCT00784121

Primary: The absence of primary and accumulated dermical irritability and dermical sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale. (Throughout the study)Enrollment:54/54Sites: 1NON_RANDOMIZED, SUPPORTIVE_CARE

Phase 3Q4 2008Dermacyd Breeze Pocket BR (Lactic Acid)HygieneNCT00793026

Primary: Absence of irritation (Throughout the study)Enrollment:30/30Sites: 1NON_RANDOMIZED, SUPPORTIVE_CARE

Phase 2Q4 2008IniparibPrimary Peritoneal Cancer, Advanced Epithelial Ovarian CancerNCT00677079

Primary: Best overall response (until treatment discontinuation (assessment at the at the end of each 8-week cycle))Enrollment:12/12Sites: 1NA, TREATMENT

Phase 3Q4 2008DTaP-HB PRP~T Combined VaccineDiphtheria, Tetanus, PertussisNCT00514709

Primary: Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) (Day 0 (pre-vaccination) and Day 28 post-booster vaccination)Enrollment:1,843/1,843Sites: 7RANDOMIZED, PREVENTION

Phase 3Q1 2009Meningococcal Polysaccharide Diphtheria Conjugate VaccineMeningococcal Meningitis, Measles, MumpsNCT00422292

Primary: Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only) (Day 30 after the 12-month vaccination)Enrollment:1,664/1,664Sites: 88RANDOMIZED, SINGLE, PREVENTION

Phase 3NegativeQ1 2009RasburicaseHyperuricemiaNCT00607152

Primary: Mean plasma uric acid AUC0-96 (0hour, 4hour, 12 hour and q12h thereafter)Enrollment:10/10Sites: 1RANDOMIZED, TREATMENT

Phase 2Q1 2009Inactivated, split-virion, influenza vaccineInfluenza, Orthomyxovirus Infections, Myxovirus InfectionNCT00776438

Primary: To provide information concerning immune response to an inactivated, split-virion, influenza vaccine. (21 days post-vaccination)Enrollment:160/160Sites: 1RANDOMIZED, PREVENTION

Phase 3NegativeQ1 2009RimonabantObesity, Diabetes Mellitus Type 2NCT00478595

Primary: Absolute change from baseline in HbA1C (Baseline to week 52)Enrollment:458/458Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2009Meningococcal polysaccharide diphtheria toxoid conjugateMeningitis, MeningococcemiaNCT00700713

Primary: Percentage of Participants With Serum Meningococcal Serogroups A, C, Y, and W-135 Bactericidal Antibody Titers ≥ 1:4 and ≥ 1:8 Before and Following Vaccination With Menactra® (Day 0 (pre-vaccination) and Day 30 post-vaccination)Enrollment:181/181Sites: 13NON_RANDOMIZED, PREVENTION

Phase 2Q1 2009SSR180575Diabetic NeuropathiesNCT00502515

Primary: Rate of epidermal nerve fiber regeneration (24 weeks)Enrollment:309/309Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2009docetaxelNasopharyngeal Neoplasms, CarcinomaNCT00565448

Primary: Number of Participants With Complete Response (CR) (after the completion of the induction treatment (up to 9 weeks))Enrollment:75/75Sites: 26RANDOMIZED, TREATMENT

Phase 3Q1 2009eplivanserin (SR46349)Sleep Initiation and Maintenance DisordersNCT00679900

Primary: Sleepiness in the morning measured on a visual analog scale of the patient's sleep questionnaire (4 weeks)Enrollment:283/283Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2009TdcP-IPV vaccineDiphtheria, Tetanus, PertussisNCT00797511

Primary: Number of Participants With Seroprotection to Vaccine Antigens Following Vaccination With ADACEL Polio (TdcP-IPV) Vaccine. (Day 28 post-vaccination)Enrollment:132/132Sites: 1NA, PREVENTION

Phase 3PositiveQ2 2009Japanese encephalitis vaccineJapanese Encephalitis, Hepatitis ANCT00735644

Primary: Number of Participants With Seroconversion to Vaccine Antigens Following Vaccination With JE-CV by GPO MBP Lots (Day 0 (pre-vaccination) and Day 28 post-vaccination)Enrollment:1,200/1,200Sites: 8RANDOMIZED, SINGLE, PREVENTION

Phase 3NegativeQ2 2009AVE5530HypercholesterolemiaNCT00741715

Primary: Percent change from baseline in calculated LDL-C (At week 12)Enrollment:1,736/1,736Sites: 2RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2009G-CSF plus plerixaforNon-Hodgkin Lymphoma, Hodgkin DiseaseNCT00444912

Primary: Summary of Adverse Events (AEs) (Day 1 and up to Day 59 (maximum time before start of chemotherapy))Enrollment:30/30Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q2 2009Semuloparin sodiumVenous ThromboembolismNCT00697099

Primary: Percentage of Participants Who Experienced Venous Thromboembolism Event [VTE] or Death From Any Cause (From randomization up to 10 days after surgery or the day of mandatory venography, whichever came first)Enrollment:2,326/2,326Sites: 30RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q2 2009Inactivated, split-virion influenza vaccineOrthomyxoviridae Infection, Influenza, Myxovirus InfectionNCT00383526

Primary: To provide information concerning the immunogenicity of Inactivated, Split-Virion Influenza vaccine (21 days post-vaccination)Enrollment:3,707/3,707Sites: 4RANDOMIZED, PREVENTION

Phase 2PositiveQ2 2009Polysaccharide Diphtheria Toxoid Conjugate VaccineMeningococcal Meningitis, Tetanus, DiphtheriaNCT00355121

Primary: Number of Participants With Antibodies Against Diphtheria and Tetanus at ≥ 1.0 IU/mL After DAPTACEL Vaccination (Day 30 post-vaccination (Visit 1))Enrollment:882/882Sites: 26RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2PositiveQ2 2009TeriflunomideMultiple SclerosisNCT00489489

Primary: Overview of Adverse Events [AE] (from first study drug intake up to 112 days after last intake or up to the first intake in the extension study LTS6047, whichever occured first (40 weeks max))Enrollment:118/118Sites: 5RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2009NerispirdineMultiple Sclerosis, Optic Nerve, NeuritisNCT00772525

Primary: Visual Evoked Potential (P100) latency (pre-dose and post-dose of each treatment intake (3))Enrollment:31/31Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2009LACTIC ACID(ND)HygieneNCT00933413

Primary: Evaluation of the absence of irritation and the good acceptability by using one specific scale which describes the intensity of the reaction. (From the treatment start to the end of the study (treatment period 21 consecutive days))Enrollment:30/30Sites: 1NON_RANDOMIZED, PREVENTION

Phase 3Q3 2009LACTIC ACID(ND)HygieneNCT00933842

Primary: Measure of the photo irritation test and the photosensitivity by using UVA irradiation and evaluation according to International Contact Dermatitis Research Group (ICDRG) scale. Evaluation of the sensibility according to the skin type. (From the treatment start to the end of the study (treatment duration 5 weeks))Enrollment:27/27Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q3 2009docetaxel and carboplatinLung NeoplasmsNCT00826852

Primary: Efficacy by response rate (After the 3rd cycle, 6th cycle and at every follow up visit)Enrollment:49/49Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q3 2009LACTIC ACID(ND)HygieneNCT00933257

Primary: Measure of the photo irritation test and the photosensitivity byusing UVA irradiation and evaluation according to International Contact Dermatitis Research Group (ICDRG) scale. Evaluation of the sensibility according to the skin type. (From the treatment start to the end of the study (treatment period 5 weeks))Enrollment:27/27Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q3 2009LACTIC ACID(ND)HygieneNCT00933907

Primary: Evaluation of the absence of primary and accumulated dermical irritability and dermical sensitivity by using International Contact Dermatitis Research Group (ICDRG) scale. (From the treatment start to the end of the study( treatment period 6 weeks))Enrollment:55/55Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ3 2009Docetaxel + Estramustine + HydrocortisoneProstatic NeoplasmsNCT00705822

Primary: Response rate over 50% in PSA (every 3 weeks up to end of treatment and every month until PSA progression)Enrollment:54/54Sites: 1RANDOMIZED, TREATMENT

Phase 3Q3 2009LACTIC ACID(ND)HygieneNCT00932945

Primary: Evaluation of the absence of irritation and the good acceptability by using one specific scale which describes the intensity of the reaction. (From the treatment start up to the end of the study (treatment period 21 days))Enrollment:32/32Sites: 1NON_RANDOMIZED, PREVENTION

Phase 2NegativeQ3 2009AVE1625SchizophreniaNCT00439634

Primary: Change from baseline in the MATRICS Cognitive Battery composite standardized score (at week 24)Enrollment:873/873Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ4 2009TeriflunomideMultiple SclerosisNCT00475865

Primary: Overview of Adverse Events (AE] (from first study drug intake up to 112 days after last intake or up to the first intake in the extension study LTS6047, whichever occured first (40 weeks max))Enrollment:123/123Sites: 6RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ4 2009Insulin Glargine (LANTUS)AMINCT00670228

Primary: Infarct Size Absolute Change From Baseline at Day 60 (From baseline at Day 60)Enrollment:34/34Sites: 5RANDOMIZED, TREATMENT

Phase 2Q4 2009gemcitabine/carboplatinBreast CancerNCT00540358

Primary: Clinical benefit rate (until cut-off date established so that all patients were evaluable for primary outcome measure)Enrollment:123/123Sites: 18RANDOMIZED, TREATMENT

Phase 3Q4 2009REPEVAXHealthyNCT00928785

Primary: Anti-tetanus seroprotection rate (defined as the percentage of subjects with anti-tetanus antibody titre (ELISA) ≥ 0.1 IU/mL) (10 days)Enrollment:52/52Sites: 9RANDOMIZED, PREVENTION

Phase 2Q4 20092009-2010 Trivalent Influenza Virus VaccineInfluenzaNCT00988143

Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Quadrivalent Influenza Vaccine or Fluzone® Trivalent Influenza Vaccines. (Day 0 up to 7 days post-vaccination)Enrollment:600/600Sites: 4RANDOMIZED, PREVENTION

Phase 2Q1 2010IRBESARTAN (SR47436)HypertensionNCT00950066

Primary: Difference in mean change in SeDBP between each FDC, its individual constituents administered as monotherapy and placebo (At week 0, week 2, week 4 and week 8)Enrollment:270/270Sites: 4RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ1 2010VandetanibNSCLCNCT00777179

Primary: Progression-free Survival (PFS) Rate at 3 Months (12 weeks)Enrollment:117/117Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2010Clopidogrel (SR25990)Heart Defects, CongenitalNCT00396877

Primary: Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature) (Median follow-up of 5.8 months (up to a maximum of 12 months after randomization))Enrollment:906/906Sites: 31RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2010Oxaliplatin + 5-Fluorouracil/LeucovorinCarcinoma, HepatocellularNCT00471965

Primary: Overall survival (From the date of randomization to the date of death due to any cause)Enrollment:371/371Sites: 4RANDOMIZED, TREATMENT

Phase 2Q2 2010Docetaxel + OxaliplatinStomach NeoplasmsNCT00382720

Primary: Time to Progression (every 8 weeks up to a maximum of 36 months)Enrollment:275/275Sites: 12RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2010vandetanibProstate CancerNCT00686036

Phase 3Q3 2010Semuloparin SodiumVenous ThromboembolismNCT00679588

Primary: Percentage of Participants Who Experience Venous Thromboembolism Event (VTE) or All-cause Death (From randomization up to 10 days after surgery or the day of mandatory venography, whichever comes first)Enrollment:4,413/4,413Sites: 270RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q3 2010ATN-103 10 mg q4wksRheumatoid ArthritisNCT01007175

Primary: Safety and tolerability will be evaluated on the basis of AEs, SAEs,(including injection site reactions and infections), physical examination findings, vital sign, measurements, immunogenicity assessments, early termination, and clinical laboratory test. (20 weeks)Enrollment:60/60Sites: 15RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2010JE-CV VaccineJapanese Encephalitis, VaricellaNCT01190228

Primary: Percentage of Participants With JE Seroprotection Before and Following a Dose of Live Attenuated JE-CV (Day 0 (pre-vaccination) and Day 7 and Day 28 post-vaccination)Enrollment:454/454Sites: 1RANDOMIZED, PREVENTION

Phase 3Q4 2010Idrabiotaparinux sodiumEmbolism, ThrombosisNCT00345618

Primary: Recurrence of symptomatic, fatal or not, VTE (PE or DVT) as confirmed by a Central Independent Adjudication Committee (CIAC) (3 months)Enrollment:3,202/3,202Sites: 38RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q4 2010Generic = PlerixaforLymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma, Front Line MobilizationNCT00838357

Primary: To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplant (24 months)Enrollment:118/118Sites: 26NA, TREATMENT

Phase 2NegativeQ4 2010Ferroquine (SSR97193)Plasmodium Falciparum InfectionNCT00988507

Primary: Recrudescent infections at D28 in the groups with ferroquine associated with artesunate. Recrudescence is defined as the recurrence of the same original strain of Plasmodium falciparum regardless of clinical symptoms (4 weeks)Enrollment:Target 440Sites: 10RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 2010Docetaxel (TAXOTERE®) ChemotherapyProstatic NeoplasmsNCT00283062

Primary: Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression (from the date of surgery up to 3 years after randomization of the last participant)Enrollment:228/228Sites: 17RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2011Lixisenatide (AVE0010)Diabetes Mellitus, Type 2NCT00763451

Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24)Enrollment:484/484Sites: 15RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2011SSR125543Major DepressionNCT01034995

Primary: Change from baseline (Day -1) to Day 56 in the 17-item HAM-D total score (8 weeks)Enrollment:Target 580Sites: 73RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2011Lixisenatide (AVE0010)Type 2 Diabetes MellitusNCT00976937

Primary: Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24 (Week 24)Enrollment:319/319Sites: 92RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2011IniparibBreast Cancer, MetastaticNCT01045304

Primary: Overall response rate (ORR) (Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months))Enrollment:163/163Sites: 20RANDOMIZED, TREATMENT

Phase 2Q2 2011ALX-0081Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)NCT01020383

Primary: Incidence and severity of bleeding classified by the following criteria: TIMI major bleeding events, TIMI minor bleeding events, bleeding events requiring medical attention, defined as TIMI minimal bleeding events (30 days)Enrollment:364/364Sites: 39RANDOMIZED, TREATMENT

Phase 2Q2 2011DRONEDARONE (SR33589)Atrial FibrillationNCT01213368

Primary: Change from baseline in mean ventricular rate measured by 24-hour Holter Electrocardiogram (ECG) (Day 14)Enrollment:181/181Sites: 25RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 20110.9% Normal SalineDiarrhea, Clostridium Difficile InfectionNCT00772343

Primary: Recurrence of Clostridium difficile infection. (Approximately 13 weeks after last injection)Enrollment:116/116Sites: 31RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2011Lixisenatide (AVE0010)Type 2 Diabetes MellitusNCT00975286

Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24)Enrollment:446/446Sites: 140RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2011DTaP//PRP-T Combined VaccineDiphtheria, Tetanus, PertussisNCT01062477

Primary: Immunogenicity: To provide information concerning the immunogenicity of ACTACEL vaccine after primary and booster vaccination. (One month post-vaccination)Enrollment:1,056/1,056Sites: 2RANDOMIZED, PREVENTION

Phase 2PositiveQ3 2011SarilumabRheumatoid ArthritisNCT01217814

Primary: Percentage of Participants Who Achieved at Least 20% Improvement in American College of Rheumatology (ACR20) Core Set Disease Activity Index at Week 12 (Week 12)Enrollment:16/16Sites: 14RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2011Doxorubicin and cyclophosphamide (AC) + bevacizumabBreast CancerNCT00365365

Primary: Cardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF) (from the first dose of study medication up to the end of follow-up (up to 3 yrs))Enrollment:214/214Sites: 1RANDOMIZED, TREATMENT

Phase 3PositiveQ4 2011DTaP-IPV-Hep B-PRP-T VaccineDiphtheria, Tetanus, Whooping CoughNCT01177722

Primary: Geometric Mean Titers (GMTs) of Anti-Hepatitis B Before and After 3 Dose Primary Vaccination With Either DTaP-IPV-Hep B-PRP~T Batch A, B, or C, or Infanrix Hexa™ (Day 0 (pre-vaccination) Dose 1 and 30 days post-vaccination)Enrollment:1,375/1,375Sites: 2RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2NegativeQ4 2011IniparibNon-small Cell Lung Cancer Stage IVNCT01086254

Primary: overall response rate (ORR) that is defined in the RECIST 1.1 version, as: complete response rate + partial response rate (up to a maximum follow-up of 25 weeks)Enrollment:119/119Sites: 14RANDOMIZED, TREATMENT

Phase 3Q4 2011insulin glargine (HOE901)Diabetes Mellitus, Non-Insulin-DependentNCT00069784

Primary: Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke (from randomization until study cut-off date (median duration of follow-up: 6.2 years))Enrollment:12,537/12,537Sites: 40RANDOMIZED, TREATMENT

Phase 3Q4 2011Licensed 2010-2011 Trivalent Influenza Vaccine, No PreservativeInfluenzaNCT01240746

Primary: Geometric Mean Titers Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants (Day 28 post final vaccination)Enrollment:4,363/4,363Sites: 67RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2PositiveQ4 2011AlirocumabHypercholesterolemiaNCT01288443

Primary: Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis (Baseline to Week 12 (LOCF))Enrollment:183/183Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2012teriflunomideMultiple SclerosisNCT01403376

Primary: Percentage of Participants With Antibody Titer ≥40 at 28 Days Post Vaccination (28 days post vaccination)Enrollment:128/128Sites: 14NON_RANDOMIZED

Phase 2Q1 2012ombrabulin (AVE8062)Non-small Cell Lung CancerNCT01263886

Primary: Progression free survival (PFS) (approximately 1.5 years)Enrollment:176/176Sites: 43RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2012Semuloparin sodiumThrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)NCT01567904

Primary: Pharmacokinetics: Plasma concentrations of Semuloparin (6 samples; 0.5-1h and 6h after D4 injection, 1.5-4h and 12h after D5 injection, just before and 8h after D6 injection)Enrollment:2/2Sites: 1NON_RANDOMIZED, PREVENTION

Phase 3Q3 2012Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®Meningitis, Meningococcal InfectionNCT01359449

Primary: Geometric Mean Titers of Serum Bovine Albumin Baby Rabbit Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age. (28 days post-vaccination)Enrollment:123/123Sites: 1RANDOMIZED, PREVENTION

Phase 3Q3 2012SENNA+CASSIAConstipationNCT00994851

Primary: Evaluation of the evacuation frequency during the treatment and follow-up period (30 and 45 days)Enrollment:96/96Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2012Meningococcal polysaccharide diphtheria toxoid conjugateMeningitis, Meningococcal Meningitis, Meningococcal InfectionsNCT01519713

Primary: Number of Participants With Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers of >=1:128 Following Vaccination With One Dose of Menactra® Vaccine (28 Days post-vaccination)Enrollment:200/200Sites: 3NON_RANDOMIZED, PREVENTION

Phase 3NegativeQ3 2012DocetaxelProstatic NeoplasmsNCT00514917

Primary: Median Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population (Randomization until PSA progression or radiographic progression or death due to prostate cancer, assessed up to Month 60)Enrollment:413/413Sites: 9RANDOMIZED, TREATMENT

Phase 3Q4 2012Quadrivalent Influenza Vaccine (split virion, inactivated)InfluenzaNCT01481454

Primary: Percentage of participants reporting solicited injection site reactions and solicited systemic reactions during the trial (Day 0 to 7 post-vaccination)Enrollment:1,701/1,701Sites: 6RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q4 2012paclitaxelBreast Cancer FemaleNCT01204125

Primary: Pathological Complete Response (pCR) rate defined as the complete absence of invasive carcinoma on histological examination of the breast at the time of definitive surgery and confirmed by blinded centralized review (at the time of definitive surgery)Enrollment:141/141Sites: 25RANDOMIZED, TREATMENT

Phase 2Q4 2012(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular PertussisPertussis, Tetanus, DiphtheriaNCT01689324

Primary: Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL® (Day 28 post-vaccination)Enrollment:43/43Sites: 3NA, PREVENTION

Phase 2Q4 2012Clostridium difficile toxoids A and B (Low-dose with adjuvant)Clostridium Difficile Infection, DiarrheaNCT01230957

Primary: Information concerning the safety profile in terms of solicited and unsolicited reactions in participants following vaccination with ACAM-CDIFF™ Vaccine. (6 days after each vaccination and up to 6 months post-vaccination 3)Enrollment:650/650Sites: 30RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q4 2012XL147 (SAR245408)Breast Cancer, Breast NeoplasmsNCT01042925

Primary: Safety and tolerability of XL147 in combination with trastuzumab and in combination with trastuzumab and paclitaxel (safety assessments at weekly study visits)Enrollment:42/42Sites: 9NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2012SAR279356Infection ProphylaxisNCT01389700

Primary: Pharmacokinetics parameters of SAR279356 : Ceoi, AUClast and CL (90 days)Enrollment:7/7Sites: 6RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q1 2013SAR113945Knee OsteoarthritisNCT01598415

Primary: Womac Pain Score (5 items) (at 8 weeks)Enrollment:130/130Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2013Live attenuated Japanese encephalitis chimeric virus vaccineJapanese Encephalitis, Japanese Encephalitis Virus DiseaseNCT01396512

Primary: Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine (Day 28 post-vaccination)Enrollment:274/274Sites: 6RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q2 2013Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella VirusTetanus, Diphtheria, PertussisNCT01346293

Primary: Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine (Day 0 (pre-vaccination) and Day 28 post-vaccination)Enrollment:3,372/3,372Sites: 72RANDOMIZED, PREVENTION

Phase 3Q2 2013IBUPROFEN + CAFFEINEPainNCT01426971

Primary: Number of patients with reduction of at least 30mm in the visual scale (VAS) of pain (from baseline to 60 minutes)0RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2013SAR3419Diffuse Large B-Cell LymphomaNCT01470456

Primary: Number of participants achieving an Objective Response Rate (18 weeks)Enrollment:50/50Sites: 13NA, TREATMENT

Phase 3PositiveQ3 2013AlirocumabHypercholesterolemiaNCT01644474

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis (From Baseline to Week 24)Enrollment:103/103Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2013Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virusDengue, Dengue Fever, Dengue Hemorrhagic FeverNCT01488890

Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2 (Pre-injection 1, 28 days and 6 months post-injection 3)Enrollment:390/390Sites: 7RANDOMIZED, PREVENTION

Phase 3Q3 2013HOE901-U300 (Insulin glargine new formulation)Type 1 Diabetes MellitusNCT01683266

Primary: Change In HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6)Enrollment:549/549Sites: 147RANDOMIZED, TREATMENT

Phase 3Q4 2013Insulin glargine new formulation (HOE901)Type 1 Diabetes MellitusNCT01689129

Primary: Change from baseline in HbA1c (baseline, 6 months)Enrollment:243/243Sites: 22RANDOMIZED, TREATMENT

Phase 3PositiveQ4 2013SarilumabRheumatoid ArthritisNCT01061736

Primary: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12)Enrollment:1,675/1,675Sites: 262RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2013Vandetanib 300mgUnresectable Locally Advanced or Metastatic, Medullary Thyroid CarcinomaNCT01661179

Primary: Objective Response Rate Within the First 56 Weeks After the First Dose of Vandetanib (Sept 2012 to May 2014)Enrollment:14/14Sites: 4NA, TREATMENT

Phase 2PositiveQ1 2014AlirocumabHypercholesterolemiaNCT01812707

Primary: Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis (Baseline to Week 12 (LOCF))Enrollment:100/100Sites: 4RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2014oxaliplatin (SR96669)Hepatic Neoplasm MalignantNCT01245582

Primary: Overall Survival (OS) (From the date of randomization to the date of death due to any cause.)0RANDOMIZED, TREATMENT

Phase 2Q3 2014Ombrabulin (AVE8062)Ovarian Cancer RecurrentNCT01332656

Primary: Progression Free Survival (PFS) (approximately 24 months)Enrollment:154/154Sites: 38RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2014sevelamer carbonate 800mgRenal Failure ChronicNCT02332811

Primary: The reduction in serum phosphorus from baseline to end of study with Sevelamer carbonate tablets 800 mg and Sevelamer carbonate Powder 2.4 g in chronic kidney disease (CKD) patients both on haemodialysis and not on dialysis (up to 8 weeks)Enrollment:96/96Sites: 1RANDOMIZED, TREATMENT

Phase 2Q3 2014Purified Vero Rabies Vaccine Serum Free (VRVg)RabiesNCT01930357

Primary: Number Subjects with rabies virus neutralizing antibody (RVNA) titer ≥ 0.5 IU/mL as measured by rapid fluorescent focus inhibition test (RFFIT) (Day 42)Enrollment:342/342Sites: 2RANDOMIZED, SINGLE, PREVENTION

Phase 3Q3 2014Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbedTetanus, Diphtheria, PertussisNCT02089347

Primary: Percentage of Participants With Diphtheria and Tetanus Post-vaccination Booster Response Following Vaccination With Either SP306 or DT (Day 28 post-vaccination)Enrollment:534/534Sites: 19RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2PositiveQ4 2014CYD Dengue vaccineDengue Fever, Dengue Hemorrhagic Fever, Dengue VirusNCT00880893

Primary: Percentage of All Participants Reporting Solicited Injection-site and Systemic Reactions Following Each Injection With CYD Dengue Vaccine or Placebo (Day 0 up to 14 days post-any and each injection)Enrollment:1,198/1,198Sites: 5RANDOMIZED, TRIPLE, PREVENTION

Phase 2Q4 2014Placebo (for dupilumab)Nasal PolypsNCT01920893

Phase 3PositiveQ4 2014Placebo (for alirocumab)HypercholesterolemiaNCT01507831

Primary: Percentage of Participants Who Experienced Adverse Events (AEs) (Up to 10 weeks after last study drug administration (maximum of 86 weeks))Enrollment:2,341/2,341Sites: 320RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2014Lixisenatide (AVE0010)Type 2 DiabetesNCT01768559

Primary: Change in HbA1c From Baseline to Week 26 (Baseline, Week 26)Enrollment:894/894Sites: 199RANDOMIZED, TREATMENT

Phase 3Q4 2014DoxorubicinBreast NeoplasmsNCT00021255

Primary: Percentage of Participants With Disease Free Survival at 5 Years (From randomization until relapse or death or up to 5 years)Enrollment:3,222/3,222Sites: 42RANDOMIZED, TREATMENT

Phase 2Q1 2015teriflunomide (HMR1726)Multiple SclerosisNCT00228163

Primary: Number of patients with adverse events (Up to a maximum of 532 weeks (4 weeks after last treatment intake) or until teriflunomide is commercially available in the country where patient lives)Enrollment:147/147Sites: 16RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2015SarilumabRheumatoid ArthritisNCT01764997

Primary: Change From Baseline in Disease Activity Score for 28 Joints - C-Reactive Protein (DAS28-CRP) Score at Week 24 (Baseline, Week 24)Enrollment:776/776Sites: 257RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2015Lixisenatide (AVE0010)Acute Coronary SyndromeNCT01147250

Phase 3Q1 2015HBVAXPRO 5µgVirus Diseases, Hepatitis BNCT02012998

Primary: Percentage of subjects with an anti-hepatitis B concentration ≥10 mIU/mL (One month after the challenge dose)Enrollment:751/751Sites: 10NA, PREVENTION

Phase 3Q1 2015Lixisenatide (AVE0010)Type 2 DiabetesNCT01798706

Primary: Absolute Change in HbA1c From Baseline to Week 24 (Baseline, Week 24)Enrollment:350/350Sites: 83RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2015SarilumabRheumatoid ArthritisNCT01709578

Primary: Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24 (Week 24)Enrollment:546/546Sites: 196RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2015Agalsidase betaFabry DiseaseNCT00701415

Primary: Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium (Baseline, Week 52, Week 156 and Week 260)Enrollment:31/31Sites: 12RANDOMIZED, TREATMENT

Phase 3Q3 2015Insulin glargine/lixisenatide (HOE901/AVE0010)Type 2 DiabetesNCT02058160

Phase 2NegativeQ3 2015LIXISENATIDE AVE0010Type II Diabetes MellitusNCT02274740

Primary: Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min) (After 10 weeks of treatment)Enrollment:2/2RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2016SarilumabRheumatoid ArthritisNCT02332590

Phase 3Q1 2016AVANAFILSexual Function and Fertility Disorders NEC-Erectile DysfunctionNCT02503306

Primary: Change in the percentage of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse (12 weeks)Enrollment:189/189Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2016Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)Japanese EncephalitisNCT02492165

Primary: Number of Participants With Solicited Injection Site Reactions and Systemic Events Following a Single Primary Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) (Day 0 up to Day 14 post-vaccination)Enrollment:250/250Sites: 1NON_RANDOMIZED, PREVENTION

Phase 3Q2 2016Placebo (for Alirocumab)HypercholesterolemiaNCT02289963

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis (From Baseline to Week 24)Enrollment:199/199Sites: 27RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2016DTaP-IPV-Hep B-PRP~T combined vaccineDiphtheria, Tetanus, PertussisNCT02094833

Primary: Number of participants with anti-Diphtheria antibody concentrations ≥ 0.01 International Units (IU)/mL (1 month post third vaccination)Enrollment:310/310Sites: 16RANDOMIZED, PREVENTION

Phase 2Q3 2016ALX-0061Rheumatoid ArthritisNCT02287922

Primary: Number and Percentage of Subjects With American College of Rheumatology 20 (ACR20) at Week 12 (Week 12)Enrollment:251/251Sites: 83RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2016CYD Dengue Vaccine (5-dose formulation)Dengue Fever, Dengue Hemorrhagic FeverNCT02623725

Primary: Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group (28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64)Enrollment:251/251Sites: 5RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q4 2016Insulin glargine (U300)Type 2 Diabetes MellitusNCT02585674

Primary: Percentage of patients reaching fasting SMPG target range 90-130 mg/dL (5.0-7.2 mmol/L) at Week 16 (mean of the last 5 readings recorded over the last 2 weeks) without a severe hypoglycemic episode during the 16-week on-treatment period (Baseline to Week 16)Enrollment:151/151Sites: 19RANDOMIZED, TREATMENT

Phase 2Q4 2016Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate VaccineMeningitis, Meningococcal Meningitis, Meningococcal InfectionsNCT02640404

Phase 2Q1 2017Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1Tetanus, Diphtheria, PertussisNCT02587520

Primary: Number of Participants With Solicited Injections Site or Systemic Reactions Following Vaccination at Day 0: Aged 10-18 Years (Within 7 days after vaccination)Enrollment:1,363/1,363Sites: 20RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3PositiveQ2 2017AlirocumabHypercholesterolemiaNCT02584504

Primary: Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis (From Baseline to Week 12)Enrollment:163/163Sites: 30RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2017placeboOsteoarthritisNCT02845271

Phase 3PositiveQ2 2017AlirocumabHypercholesterolemiaNCT01954394

Primary: Percentage of Participants Who Experienced Adverse Events (AEs) (Up to 10 weeks after last study drug administration (maximum of 176 weeks))Enrollment:986/986Sites: 177NA, TREATMENT

Phase 2PositiveQ4 2017SAR425899Type 2 Diabetes MellitusNCT02973321

Primary: Change From Baseline in HbA1c to Week 26 (Baseline, Week 26)Enrollment:296/296Sites: 59RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2018PlaceboAsthmaNCT02573233

Phase 3Q1 2018Multi-dose Quadrivalent Influenza VaccineInfluenzaNCT03391193

Phase 2NegativeQ2 2018Cabazitaxel XRP6258Prostate Cancer MetastaticNCT02379390

Phase 3Q3 2018Insulin aspartType 1 Diabetes Mellitus-Type 2 Diabetes MellitusNCT03211858

Phase 3Q3 2018MenACYW conjugate vaccineMeningitis, MeningococcalNCT03205371

Phase 3PositiveQ3 2018Dupilumab SAR231893 (REGN668)Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSw NP)NCT02898454

Primary: Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score (Baseline, Week 24)Enrollment:448/448Sites: 123RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2018ALX-0061Rheumatoid ArthritisNCT02518620

Primary: Number and Percentage of Subjects With American College of Rheumatology (ACR) 20 Response. (At Weeks 0, 12, 48, and 104)Enrollment:406/406Sites: 57NA, TREATMENT

Phase 3Q4 2018PVRVRabiesNCT01622062

Phase 3NegativeQ1 2019Insulin glargine/LixisenatideType 2 Diabetes MellitusNCT03434119

Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 (Baseline, Week 26)Enrollment:241/241Sites: 85RANDOMIZED, TREATMENT

Phase 2PositiveQ1 2019SAR156597Systemic SclerosisNCT02921971

Primary: Change From Baseline in Modified Rodnan Skin Score to Week 24 (Baseline, Week 24)Enrollment:97/97Sites: 44RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2019HDCVHealthy Volunteers (Rabies Immunization)NCT03700242

Phase 3Q1 2019Docetaxel (XRP6976)Gastric CancerNCT01515748

Phase 3Q1 2019PlaceboOsteoarthritisNCT03190369

Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 Pain (Walking Pain) Subscale Score Over 26 Weeks (From Baseline up to Week 26)Enrollment:440/440Sites: 21RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ3 2019SAR422459Stargardt's DiseaseNCT01367444

Phase 3Q3 2019PlaceboHyperphosphatemiaNCT03001011

Primary: Change From Baseline in Serum Phosphorus at Week 8 (Baseline, Week 8)Enrollment:202/202Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2019Avalglucosidase alfa (GZ402666)Glycogen Storage Disease Type II-Pompe's DiseaseNCT03019406

Primary: PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) (From Baseline to Week 25)Enrollment:22/22Sites: 12RANDOMIZED, TREATMENT

Phase 2Q4 2019SAR440340Chronic Obstructive Pulmonary DiseaseNCT03546907

Primary: Annualized Rate of Moderate to Severe Acute Exacerbation Events in Chronic Obstructive Pulmonary Disease (AECOPD) Participants (From Baseline up to Week 52)Enrollment:343/343Sites: 83RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2019DupilumabAsthmaNCT02134028

Phase 2PositiveQ4 2019Olipudase alfaSphingomyelin LipidosisNCT02292654

Phase 2PositiveQ4 2019PRN1008Pemphigus VulgarisNCT02704429

Phase 3PositiveQ1 2020DupilumabAtopic DermatitisNCT03912259

Primary: Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16 (Baseline, Week 16)Enrollment:165/165Sites: 27RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2020Alirocumab SAR236553 (REGN727)HypercholesterolemiaNCT03510715

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis (Baseline to Week 12)Enrollment:18/18Sites: 10NA, TREATMENT

Phase 3Q1 2020Avalglucosidase alfa (GZ402666)Glycogen Storage Disease Type II;Pompe's DiseaseNCT02782741

Phase 3Q3 2020Insulin Aspart SAR341402Type 1 Diabetes MellitusNCT03874715

Primary: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Timepoint (AUClast) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm) (0 hour (hr)(Pre-dose), 10, 20, 30, 40 & 50 minutes (min), 1hr, 1hr-10, 20, 30, 40 & 50min, 2hr, 2hr-15, 30 & 45min, 3hr, 3hr-15, 30 & 45min, 4hr, 4hr-20 & 40min, 5hr, 5hr-20 & 40min, 6hr, 6hr-30min, 7hr, 7hr-30min & 8hr post-dose on Day 112)Enrollment:210/210Sites: 33RANDOMIZED, TREATMENT

Phase 3NegativeQ3 2020Sarilumab SAR153191Corona Virus InfectionNCT04327388

Primary: Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points (Baseline to Day 29)Enrollment:420/420Sites: 47RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2020CaplacizumabAcquired Thrombotic Thrombocytopenic PurpuraNCT02878603

Phase 3Q4 2020INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010Type 2 Diabetes MellitusNCT03767543

Primary: Change in glycated hemoglobin (HbA1c)% (Baseline to Week 26)Enrollment:265/265Sites: 32RANDOMIZED, TREATMENT

Phase 3NegativeQ4 2020Efpeglenatide SAR439977Type 2 Diabetes MellitusNCT03713684

Phase 3Q1 2021Alirocumab SAR236553 (REGN727)HypercholesterolaemiaNCT03510884

Phase 3PositiveQ1 2021fitusiranHemophilia A, Hemophilia BNCT03417245

Phase 3Q1 2021Insulin glargine/Lixisenatide (HOE901/AVE0010)Type 2 Diabetes MellitusNCT03798054

Primary: Change in HbA1c (From Baseline to Week 24)Enrollment:878/878Sites: 79RANDOMIZED, TREATMENT

Phase 3Q1 2021placebo (saline)Sphingomyelin LipidosisNCT02004691

Primary: Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Baseline (Baseline (Day 1))Enrollment:36/36Sites: 24RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ3 2021RilzabrutinibPemphigusNCT03762265

Phase 2Q3 2021Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIbPneumococcal ImmunizationNCT04583618

Phase 3Q4 2021Dupilumab SAR231893NeurodermatitisNCT04183335

Phase 3Q1 2022isatuximab SAR650984Plasma Cell MyelomaNCT03275285

Phase 3PositiveQ1 2022FitusiranHemophiliaNCT03549871

Phase 2Q1 2022Quadrivalent Inactivated Influenza High DoseInfluenza Immunization, Healthy VolunteersNCT04969276

Phase 3Q1 2022Dupilumab SAR231893 (REGN668)AsthmaNCT03620747

Phase 3Q1 2022Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate VaccineHealthy Volunteers (Meningococcal Infection)NCT03630705

Phase 2NegativeQ2 2022BelumosudilDiffuse Cutaneous Systemic SclerosisNCT04680975

Phase 3Q2 2022Dupilumab SAR231893AsthmaNCT03782532

Phase 2Q2 2022Yellow fever vaccine (produced on serum-free Vero cells)Yellow FeverNCT05011123

Primary: Percentage of Yellow Fever-naive Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union (28 days post dose 1 (Day 29))Enrollment:690/690Sites: 23RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q2 2022Yellow fever vaccine (produced on serum-free Vero cells)Yellow Fever, Healthy VolunteersNCT04942210

Primary: Percentage of Yellow Fever (YF)-Naive Participants Who Achieved Seroconversion 28 Days Post Dose 1 (28 days post dose 1 (Day 29))Enrollment:568/568Sites: 11RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2NegativeQ3 2022Belumosudil (KD025)System; Sclerosis, Diffuse Cutaneous Systemic SclerosisNCT03919799

Phase 2Q3 2022SAR441344 IVMultiple SclerosisNCT04879628

Phase 3NegativeQ4 2022AmcenestrantBreast CancerNCT05128773

Phase 3Q4 2022Low Back PainNCT05137041

Phase 2Q4 2022PRN473 (SAR444727)Atopic DermatitisNCT04992546

Phase 3Q1 2023efanesoctocog alfa (BIVV001)Hemophilia ANCT04759131

Phase 3PositiveQ1 2023Dupilumab SAR231893Chronic Obstructive Pulmonary DiseaseNCT03930732

Phase 3Q1 2023Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate VaccineMeningococcal Immunisation, Healthy VolunteersNCT04936685

Primary: Group 1: Percentage of Participants With Sufficiency of Serum Bactericidal Assay Using Human Complement (hSBA) Vaccine Seroresponse at 30 Days Post Booster Dose (Baseline (Day 1) and 30 days after the MenACYW conjugate vaccine 5-year booster dose)Enrollment:209/209Sites: 26RANDOMIZED, PREVENTION

Phase 3Q1 2023FexofenadineSeasonal Allergic RhinitisNCT05692154

Phase 3Q1 2023Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)Healthy Volunteers (Meningococcal Infection)NCT03673462

Phase 3Q2 2023MenACYW conjugate vaccineMeningococcal InfectionsNCT03547271

Phase 2Q2 2023PlaceboAtopic DermatitisNCT05018806

Phase 2NegativeQ2 2023Isatuximab SAR650984Warm Autoimmune Hemolytic Anemia (w AIHA)NCT04661033

Phase 2NegativeQ3 2023THOR-707Pleural Mesothelioma, Non-small Cell Lung CancerNCT04914897

Phase 2NegativeQ3 2023PembrolizumabSquamous Cell Carcinoma of Head and NeckNCT05061420

Phase 2Q3 2023THOR-707Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular CarcinomaNCT05104567

Phase 2Q3 2023Pneumococcal Conjugate Vaccine formulation 1Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus ImmunisationNCT04398706

Phase 3NegativeQ3 2023SAR408701Non-small Cell Lung Cancer MetastaticNCT04154956

Phase 3NegativeQ4 2023Recombinant influenza vaccine (RIV4)Influenza ImmunizationNCT05513391

Phase 3PositiveQ4 2023Insulin glargine/LixisenatideType 2 Diabetes MellitusNCT05413369

Phase 2Q1 2024RilzabrutinibAsthmaNCT05104892

Phase 2NegativeQ1 2024SAR443820Amyotrophic Lateral SclerosisNCT05237284

Phase 3Q3 2024DupilumabChronic Rhinosinusitis With Nasal PolypsNCT05878093

Phase 3Q4 2024DupilumabChronic Spontaneous UrticariaNCT05526521

Phase 2Q4 2024SAR441566PsoriasisNCT06073119

Phase 2NegativeQ4 2024SAR443820Multiple SclerosisNCT05630547

Phase 3PositiveQ4 2024CaplacizumabThrombotic Thrombocytopenic PurpuraNCT05468320

Phase 3Q1 2025RilzabrutinibImmune ThrombocytopeniaNCT04562766

Phase 2NegativeQ1 2025SAR442501OsteochondrodysplasiaNCT06067425

Phase 3Q2 2025Itepekimab SAR440340Chronic Obstructive Pulmonary DiseaseNCT04701983

Phase 2Q2 2025Quadrivalent Influenza mRNA Vaccine MRT5421Influenza ImmunizationNCT06361875

Phase 3NegativeQ2 2025Low Dose (LD) RSVt vaccineRSV ImmunisationNCT06705140

Phase 3NegativeQ2 2025Doxercalciferol (GZ427397)Secondary Hyperparathyroidism-Chronic Kidney DiseaseNCT02859896

Phase 3Q3 2025AmlitelimabDermatitis AtopicNCT06130566

Phase 2Q3 2025AmlitelimabAlopecia AreataNCT06444451

Phase 2Q4 2025AmlitelimabDermatitis AtopicNCT06015308

Phase 3Q4 2025VenglustatGaucher's Disease Type IIINCT05222906

Phase 3Q4 2025Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate VaccineMeningococcal Immunisation, Healthy VolunteersNCT05794230

Phase 2NegativeQ4 2025THOR-707MetastasisNCT04009681

Phase 2Q4 2025IsatuximabRelapsed/Refractory Multiple MyelomaNCT05704049

Phase 3Q1 2026Erectile DysfunctionNCT06805513

Phase 2Q1 2026SAR443122Colitis UlcerativeNCT05588843

Phase 2Q1 2026LunsekimigDermatitis AtopicNCT06790121

Phase 3Q1 2026avalglucosidase alfaGlycogen Storage Disease Type IINCT04910776

Phase 2Q1 2026Pandemic flu H5 mRNA vaccineInfluenza ImmunizationNCT06727058

Phase 3Q2 2026MenACYW conjugate vaccineMeningococcal Infection, Healthy VolunteersNCT07135986

Phase 2Q2 2026DupilumabColitis UlcerativeNCT05731128

Phase 3Q2 2026Venglustat (GZ402671)Fabry DiseaseNCT05280548

Phase 3Q2 2026DupilumabLichen Simplex ChronicusNCT06687967

Phase 3Q2 2026DupilumabLichen Simplex ChronicusNCT06687980

Phase 3Q2 2026AmlitelimabDermatitis AtopicNCT06407934

Phase 2Q3 2026SAR441344 IVSystemic Lupus ErythematosusNCT05039840

Phase 2Q3 2026AmlitelimabCoeliac Disease, Celiac DiseaseNCT06557772

Phase 3Q3 2026Yellow fever vaccine (live)Yellow Fever ImmunizationNCT07103148

Phase 3Q3 2026FitusiranHemophiliaNCT03974113

Phase 2Q3 2026BelumosudilChronic Graft Versus Host DiseaseNCT05567406

Phase 2Q3 2026AmlitelimabAsthmaNCT06033833

Phase 3Q4 2026FitusiranHemophiliaNCT03754790

Phase 2Q4 2026Isatuximab intravenous (IV)Plasma Cell MyelomaNCT05669989

Phase 3Q4 2026rilzabrutinibImmune ThrombocytopeniaNCT07216079

Phase 3Q4 2026PCV21Pneumococcal InfectionsNCT06838000

Phase 2Q4 2026SAR442970Crohn's DiseaseNCT06958536

Phase 3Q1 2027PCV21Sickle Cell DiseaseNCT07247188

Phase 3Q1 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT06834347

Phase 3Q1 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT06834360

Phase 3Q1 2027efanesoctocog alfa (BIVV001)Hemophilia ANCT04644575

Phase 2Q1 2027SAR445877Solid TumorNCT05584670

Phase 2Q1 2027SAR445419Allogenic Stem Cell TransplantationNCT05726682

Phase 3Q1 2027FitusiranHemophiliaNCT05662319

Phase 3Q2 2027Isatuximab SAR650984Plasma Cell MyelomaNCT03319667

Phase 2Q2 2027SAR444336Microscopic ColitisNCT07156175

Phase 2Q2 2027FrexalimabType 1 Diabetes MellitusNCT06111586

Phase 2Q2 2027BrivekimigType 1 Diabetes MellitusNCT06812988

Phase 3Q2 2027FrexalimabMultiple SclerosisNCT06141473

Phase 3Q2 2027PCV21 vaccinePneumococcal ImmunizationNCT06736041

Phase 2Q2 2027Pentavalent Meningococcal ABCYW vaccineMeningococcal Immunization, Healthy VolunteersNCT06647407

Phase 2Q2 2027SAR402663Neovascular Age-related Macular DegenerationNCT06660667

Phase 3Q2 2027DupilumabPruritusNCT05263206

Phase 2Q2 2027LunsekimigAsthmaNCT06676319

Phase 2Q3 2027SAR441566Crohn's DiseaseNCT06637631

Phase 3Q3 2027RilzabrutinibSickle Cell DiseaseNCT06975865

Phase 2Q3 2027SAR441566Colitis UlcerativeNCT06867094

Phase 2Q3 2027BrivekimigHidradenitis SuppurativaNCT07170917

Phase 3Q3 2027PCV21 vaccinePneumococcal Immunization, Healthy VolunteersNCT06975878

Phase 3Q3 2027PCV21 vaccinePneumococcal ImmunizationNCT06824181

Phase 2Q3 2027IsatuximabPlasma Cell Myeloma RefractoryNCT04643002

Phase 2Q3 2027SAR445399Hidradenitis SuppurativaNCT07225569

Phase 2Q4 2027SAR446597Geographic AtrophyNCT07215234

Phase 3Q4 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT07484230

Phase 3Q4 2027PCV21 vaccinePneumococcal ImmunizationNCT06824194

Phase 3Q4 2027DupilumabPrurigo NodularisNCT06293053

Phase 2Q4 2027SAR445399Non-cystic Fibrosis BronchiectasisNCT07547436

Phase 3Q4 2027rilzabrutinibImmune ThrombocytopeniaNCT07007962

Phase 2Q1 2028Chlamydia mRNA VaccineChlamydia Trachomatis ImmunizationNCT06891417

Phase 2Q1 2028TeplizumabType 1 Diabetes MellitusNCT06791291

Phase 3Q1 2028FrexalimabMultiple SclerosisNCT06141486

Phase 3Q2 2028DuvakitugUlcerative ColitisNCT07184996

Phase 3Q2 2028rilzabrutinibAutoimmune Haemolytic AnaemiaNCT07086976

Phase 3Q2 2028TeplizumabType 1 Diabetes MellitusNCT07088068

Phase 3Q2 2028RilzabrutinibImmunoglobulin G4 Related DiseaseNCT07190196

Phase 2Q2 2028SAR447537Alpha 1-Antitrypsin Deficiency, EmphysemaNCT05897424

Phase 3Q3 2028DuvakitugUlcerative ColitisNCT07185009

Phase 2Q3 2028BelumosudilChronic Graft Versus Host DiseaseNCT07116031

Phase 3Q3 2028BelumosudilChronic Graft Versus Host DiseaseNCT06143891

Phase 2Q4 2028Acne mRNA vaccineAcneNCT06316297

Phase 3Q4 2028Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT07424144

Phase 3Q4 2028DupilumabWheezing, AsthmaNCT06191315

Phase 3Q1 2029AmlitelimabDermatitis AtopicNCT05492578

Phase 3Q1 2029BelumosudilLung Transplant RejectionNCT06082037

Phase 2Q1 2029SAR446268Myotonic DystrophyNCT06844214

Phase 2Q2 2029Acne mRNA vaccineAcneNCT07013747

Phase 2Q3 2029SAR448851Dementia, Alzheimer's Type, Alzheimer's DiseaseNCT07688213

Phase 3Q4 2029LunsekimigChronic Obstructive Pulmonary DiseaseNCT07190222

Phase 3Q4 2029LunsekimigChronic Obstructive Pulmonary DiseaseNCT07190209

Phase 2Q2 2030SAR444836PhenylketonuriaNCT05972629

Phase 2Q2 2030balinatunfibColitis Ulcerative, Crohn's DiseaseNCT07222189

Phase 2Q1 2031LunsekimigChronic Rhinosinusitis With Nasal PolypsNCT06914908

Phase 2Q2 2031AmlitelimabDermatitis AtopicNCT05769777

Phase 2Q2 2031Blood draw for the laboratory assessmentUsher's SyndromeNCT02065011

Phase 2Q3 2033Long term follow up in all patients who received SAR422459 in previous study TDU13583Stargardt's DiseaseNCT01736592

Phase 2TBDMitoguazoneLymphoma, Non-Hodgkin, HIV InfectionsNCT00002348

Sites: 1TREATMENT

Phase 3TBDEnoxaparin sodiumArthroplasty, Replacement, HipNCT00349180

Primary: Incidence of VTEEnrollment:Target 156Sites: 1RANDOMIZED, DOUBLE, PREVENTION

Phase 3TBDinsulin glulisineDiabetes Mellitus, Type 1NCT00290979

Primary: Non-inferiority in the efficacy and safety of HMR1964 as compared with Insulin lisproEnrollment:Target 250Sites: 1RANDOMIZED, TREATMENT

Phase 2NegativeTBDDocetaxelCarcinoma, Non-Small-Cell LungNCT00263016

Primary: Tumour response rateEnrollment:Target 50Sites: 1RANDOMIZED, TREATMENT

Phase 3NegativeTBDAlfuzosinUrinary RetentionNCT00453908

Primary: Number of patients with satisfying spontaneous voiding after 14 days measured by bladder scan at day 14.Enrollment:Target 160Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2TBDAMD3100Acute Myelogenous Leukemia, Myelodysplastic SyndromesNCT00396968

Primary: To determine if AMD3100 given in a sequential dose escalation at 80, 160 and 240 µg/kg in combination with busulfan, fludarabine (and ATG for unrelated or HLA nonidentical donors) for treatment of AML/MDS:0NON_RANDOMIZED, TREATMENT

Phase 3TBDlactoserumHygieneNCT00371852

Primary: Score evaluation of the cutaneous reaction, preconized by International Contact Dermatitis Research Group (ICDRG)Enrollment:Target 50Sites: 1NON_RANDOMIZED, TREATMENT

Sanofi

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Catalysts

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research